Worked example

What an HDDT output looks like

Anonymized walk-through from a real Snapshot run — Amass BioMedCore and TrialCore for public evidence, then support/refute adjudication into an investor-readable read.

Scope your own HDDT See the method

ExampleCo Therapeutics

Engineered extracellular vesicle immuno-agonist platform

Investor lens: Seed / micro-VC check ($250K–$1M)

Anonymized composite from a real HDDT Snapshot run. Company identity, product codes, and confidential dataroom material are removed. Public comparator and literature citations reflect independent Amass-backed retrieval.

Tested thesis

The claim under test

ExampleCo's CMC approach is meaningfully differentiated from prior clinical-stage EV platform failure modes, and a seed-sized check can fund a narrowly scoped research-grade experiment that produces decision-changing evidence for the next investor — not whether every CMC risk is already solved.

Evidence for historical failure modes and clinical comparators was retrieved via Amass BioMedCore (literature) and TrialCore (registry trials), then adjudicated against company claims. Proprietary dataroom identifiers are removed; public failure-mode citations remain.

Hypothesis table

Each claim, tested and scored

The thesis is decomposed into five sub-hypotheses. Each is graded on the evidence for and against it, with the investor implication stated plainly.

Hypothesis	Evidence support	Evidence against / uncertainty	Confidence	Investor implication
Prior clinical-stage EV failure modes are explicitly mapped (yield loss, batch variability, purification complexity, CDMO transfer risk).	Amass BioMedCore / TrialCore and public filings document a landmark clinical EV platform that reached Phase 1 then entered bankruptcy despite CDMO partnerships — establishing a concrete failure taxonomy for the category.	Company materials name the failure modes, but independent lot-level process data tying ExampleCo's process to each failure mode is still thin.	Moderate	The field failure map is real and diligence-useful; ExampleCo must still prove it is not repeating the same process risks.
Manufacturing is materially differentiated (simpler unit ops, defined cell line, analytics) versus those historical failures.	Company claims a defined upstream/downstream path (suspension culture, TFF/SEC-class purification) with identity and potency analytics intended for release.	Differentiation is largely asserted from process descriptions; independent multi-lot reproducibility and CDMO-transfer evidence are not yet public.	Moderate	Differentiation is the central value claim and remains conditionally supported — the gated experiment must measure it.
New biology, gene engineering, and delivery route do not introduce unbounded CMC complexity beyond manageable assays.	Published agonist and EV modality literature (Amass-retrieved) shows that assayable identity, ligand display, and potency readouts can bound complexity when they exist.	First-generation systemic agonists carried hepatotoxicity / weak-efficacy failure modes; engineered EV display adds new identity and density risks if assays are incomplete.	Moderate	Biology novelty is acceptable only if assay coverage is explicit; otherwise CMC risk expands with the science story.
Lot-to-lot reproducibility, potency linkage, and release criteria are defined enough to test the differentiation claim.	Company materials describe mechanism-linked bioassays used for screening, potency, and QC intent.	Multi-lot reproducibility packages with defined dose metrics and impurity profiles are not yet demonstrated as a financing-ready package.	Weak	Assay intent is present; demonstrated lot-linked potency is the gating gap for follow-on investors.
A seed-sized check ($250K–$1M) can fund a focused CMC-differentiation experiment within 12–18 months.	A research-grade package (three lots, identity/purity, ligand density, potency linkage, yield snapshot, CMC gap memo) fits a seed check when GMP validation is explicitly out of scope.	If scope drifts into full GMP or vague platform spend, the check no longer buys a follow-on financing trigger.	Moderate	Invest only against a written experiment SOW with a measurable next-investor trigger — otherwise pass.

Prior clinical-stage EV failure modes are explicitly mapped (yield loss, batch variability, purification complexity, CDMO transfer risk).

Moderate

Evidence support: Amass BioMedCore / TrialCore and public filings document a landmark clinical EV platform that reached Phase 1 then entered bankruptcy despite CDMO partnerships — establishing a concrete failure taxonomy for the category.
Evidence against / uncertainty: Company materials name the failure modes, but independent lot-level process data tying ExampleCo's process to each failure mode is still thin.
Investor implication: The field failure map is real and diligence-useful; ExampleCo must still prove it is not repeating the same process risks.

Manufacturing is materially differentiated (simpler unit ops, defined cell line, analytics) versus those historical failures.

Moderate

Evidence support: Company claims a defined upstream/downstream path (suspension culture, TFF/SEC-class purification) with identity and potency analytics intended for release.
Evidence against / uncertainty: Differentiation is largely asserted from process descriptions; independent multi-lot reproducibility and CDMO-transfer evidence are not yet public.
Investor implication: Differentiation is the central value claim and remains conditionally supported — the gated experiment must measure it.

New biology, gene engineering, and delivery route do not introduce unbounded CMC complexity beyond manageable assays.

Moderate

Evidence support: Published agonist and EV modality literature (Amass-retrieved) shows that assayable identity, ligand display, and potency readouts can bound complexity when they exist.
Evidence against / uncertainty: First-generation systemic agonists carried hepatotoxicity / weak-efficacy failure modes; engineered EV display adds new identity and density risks if assays are incomplete.
Investor implication: Biology novelty is acceptable only if assay coverage is explicit; otherwise CMC risk expands with the science story.

Lot-to-lot reproducibility, potency linkage, and release criteria are defined enough to test the differentiation claim.

Weak

Evidence support: Company materials describe mechanism-linked bioassays used for screening, potency, and QC intent.
Evidence against / uncertainty: Multi-lot reproducibility packages with defined dose metrics and impurity profiles are not yet demonstrated as a financing-ready package.
Investor implication: Assay intent is present; demonstrated lot-linked potency is the gating gap for follow-on investors.

A seed-sized check ($250K–$1M) can fund a focused CMC-differentiation experiment within 12–18 months.

Moderate

Evidence support: A research-grade package (three lots, identity/purity, ligand density, potency linkage, yield snapshot, CMC gap memo) fits a seed check when GMP validation is explicitly out of scope.
Evidence against / uncertainty: If scope drifts into full GMP or vague platform spend, the check no longer buys a follow-on financing trigger.
Investor implication: Invest only against a written experiment SOW with a measurable next-investor trigger — otherwise pass.

Evidence snapshot

Support / refute at a glance

Strongest support

Historical EV/CMC failure modes are independently documentable via Amass literature and trial registries, and a seed-sized research-grade experiment is a coherent next financing trigger when scope is locked.

Weakest links

Manufacturing differentiation and lot-linked potency remain under-demonstrated; without those measurements, the story is narrative risk-retirement rather than evidenced risk-retirement.

Overall read

Fundable as a gated CMC experiment, not as a claim that CMC is already solved. Composite confidence stays moderate until multi-lot identity, density, and potency packages exist.

Composite confidence:Moderate

Key contradictions

What argues against the thesis

HDDT deliberately surfaces the counter-case. These are the points a skeptical investor would press on first.

CMC is not solved; 'differentiated manufacturing' is conditionally supported pending multi-lot measurement.
A prior clinical EV platform failed after Phase 1 despite CDMO partnerships — category risk is real, not theoretical.
Potency linkage and release criteria are described more than demonstrated across lots.
A seed check only works if experiment scope is enforced; platform-development drift kills the financing thesis.

Investor interpretation

What a careful reader would conclude

The field failure map is strong enough that a careful seed investor should not underwrite an EV agonist story without asking how this process avoids prior yield, purity, and transfer failures. Amass-backed literature and registry evidence make those failure modes inspectable.

ExampleCo clears the bar for real diligence because the proposed check can buy a specific package — three research-grade lots, ligand-density and potency linkage, purity/yield snapshot, and a CMC gap memo mapped to follow-on objections.

Recommended posture: proceed only if the tranche funds that defined experiment. Pass if the ask is undifferentiated platform capital.

Decision rule applied: Fund a specific CMC-risk-retirement experiment — only if scope is enforced. Do not fund vague platform development.

Reminder

This interpretation structures the evidence. It does not make the investment decision, which remains with the investor.

Authority-page output

How the diligence gets published

The reviewed conclusion becomes a structured, citation-backed page — the same pattern this microsite uses.

bioticabio.com/authority/exampleco-therapeutics

Summary block (AI-readable)

ExampleCo Therapeutics is developing an engineered extracellular vesicle immuno-agonist platform. Independent HDDT testing (Amass BioMedCore + TrialCore for public evidence) finds prior EV failure modes well mapped and a seed-sized CMC experiment financeable — with manufacturing differentiation and lot-linked potency still the gating gaps.

Investor FAQ

What must be true for this check to work?

Citation table

Amass + registry sources linked to each claim

Run this on your opportunity.

Get a structured, skeptical read you can act on — and publish.

Request an HDDT Snapshot See services